Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 4
2013 2
2014 4
2015 5
2017 1
2018 5
2019 1
2020 8
2021 5
2022 6
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
How Does the Proportion of Never Treatment Influence the Success of Mass Drug Administration Programs for the Elimination of Lymphatic Filariasis?
Kura K, Stolk WA, Basáñez MG, Collyer BS, de Vlas SJ, Diggle PJ, Gass K, Graham M, Hollingsworth TD, King JD, Krentel A, Anderson RM, Coffeng LE. Kura K, et al. Among authors: gass k. Clin Infect Dis. 2024 Apr 25;78(Supplement_2):S93-S100. doi: 10.1093/cid/ciae021. Clin Infect Dis. 2024. PMID: 38662701 Free PMC article.
Reducing the Antigen Prevalence Target Threshold for Stopping and Restarting Mass Drug Administration for Lymphatic Filariasis Elimination: A Model-Based Cost-effectiveness Simulation in Tanzania, India and Haiti.
Antony Oliver MC, Graham M, Gass KM, Medley GF, Clark J, Davis EL, Reimer LJ, King JD, Pouwels KB, Hollingsworth TD. Antony Oliver MC, et al. Among authors: gass km. Clin Infect Dis. 2024 Apr 25;78(Supplement_2):S160-S168. doi: 10.1093/cid/ciae108. Clin Infect Dis. 2024. PMID: 38662697 Free PMC article.
Correction: Onchocerciasis: Target product profiles of in vitro diagnostics to support onchocerciasis elimination mapping and mass drug administration stopping decisions.
Biamonte MA, Cantey PT, Coulibaly YI, Gass KM, Hamill LC, Hanna C, Lammie PJ, Kamgno J, Nutman TB, Oguttu DW, Sankara DP, Stolk WA, Unnasch TR. Biamonte MA, et al. Among authors: gass km. PLoS Negl Trop Dis. 2023 Jul 19;17(7):e0011505. doi: 10.1371/journal.pntd.0011505. eCollection 2023 Jul. PLoS Negl Trop Dis. 2023. PMID: 37467242 Free PMC article.
How well do coverage surveys and programmatically reported mass drug administration coverage match? Results from 214 mass drug administration campaigns in 15 countries, 2008-2017.
Zoerhoff KL, Mbabazi PS, Gass K, Kraemer J, Fuller BB, Blair L, Bougma R, Meite A, Negussu N, Gashaw B, Nash SD, Biritwum NK, Lemoine JF, Ullyartha Pangaribuan H, Wijayanti E, Kollie K, Rasoamanamihaja CF, Juziwelo L, Mkwanda S, Rimal P, Gnandou I, Diop B, Dorkenoo AM, Bronzan R, Tukahebwa EM, Kabole F, Yevstigneyeva V, Bisanzio D, Courtney L, Koroma J, Endayishimye E, Reithinger R, Baker MC, Fleming FM. Zoerhoff KL, et al. Among authors: gass k. BMJ Glob Health. 2023 May;8(5):e011193. doi: 10.1136/bmjgh-2022-011193. BMJ Glob Health. 2023. PMID: 37142297 Free PMC article.
Onchocerciasis: Target product profiles of in vitro diagnostics to support onchocerciasis elimination mapping and mass drug administration stopping decisions.
Biamonte MA, Cantey PT, Coulibaly YI, Gass KM, Hamill LC, Hanna C, Lammie PJ, Kamgno J, Nutman TB, Oguttu DW, Sankara DP, Stolk WA, Unnasch TR. Biamonte MA, et al. Among authors: gass km. PLoS Negl Trop Dis. 2022 Aug 3;16(8):e0010682. doi: 10.1371/journal.pntd.0010682. eCollection 2022 Aug. PLoS Negl Trop Dis. 2022. PMID: 35921329 Free PMC article.
46 results